In this April 9, 2020 file photo, a chemist displays hydroxychloroquine tablets in New Delhi, India. U.S. regulators are revoking emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19. The Food and Drug Administration said Monday, June 15 that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. (AP Photo/Manish Swarup, File)
By Matthew Perrone
The U.S. Food and Drug Administration is revoking its emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause deadly side effects.
The agency said Monday that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs pose a greater risk to patients than any potential benefits.
The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure, and muscle or nerve damage.
The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities. The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.
On Thursday, a National Institutes of Health expert panel revised its guidelines to specifically recommend against the drug’s use except in formal studies.
Trump aggressively pushed the drug beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he took the drug preemptively against infection.
Jack Withinshaw, CCO and co-founder of Airspeeder, explains how electric flying car racing could revolutionize motorsport and the future of transportation.
TIME reveals its 2026 Best Inventions list of 300 breakthroughs, featuring Apple CEO John Ternus and the iPhone Duo as he shares his vision for the future.
Seth Goldstein, Senior Equity Analyst at Morningstar, examines Tesla’s new Roadster, SpaceX merger speculation and the race to make robotaxis profitable.
Antoine Marcel, founder and CEO of Flourish Robots, discusses how its AI-powered robot could transform household chores and bring home robotics to the masses.
Chris Stafford, haunted house expert and CEO of Thirteenth Floor Entertainment, reveals the business behind Halloween’s biggest scares and immersive attractions
Efraim Grinberg, Chairman and CEO of Movado Group, discusses keeping iconic watch brands relevant, expanding its portfolio and reaching a new generation.
The Securities & Exchange Commission wants to end the requirement that U.S. public companies file quarterly reports and move to semiannual reporting. Why?
